Nasdaq · Biotech stocks database
CLRB — Cellectar Biosciences Inc.
CLRB (Cellectar Biosciences Inc.) stock: $2.30, $21.7M market cap, $34.0M cash, -$12.3M EV, $122.4M fully diluted market cap. Next expected readout: Feb-28. Lead program: Iopofosine I 131 (Waldenstrom Macroglobulinaemia), Phase 3. Data from Fully Diluted's biotech stocks database.
Overview
Assets
Pipeline
Trials
Holders
Balance sheet
Cash $34.0M Debt $0.0M Net cash $34.0M Enterprise value -$12.3M Basic shares 8.3M shares Fully diluted shares 53.2M shares Fully diluted market cap $122.4M Cash per share $4.10
Cash figures as of 2026-06-30. Database snapshot: 2026-09-22.
Price history Loading CLRB daily closes…
Loading price history…
Upcoming catalysts Expected Drug Phase Indication Mgmt guide Oct 6 - Nov 17 CLR 131 Phase 1 Pediatric Solid Tumor; Pediatric Lymphoma; Pediatric Brain Tumor — Mar 14 - Apr 25 Iopofosine I 131 Phase 1 Breast Cancer — Feb 12 - Mar 25 Iopofosine I 131 Phase 3 Waldenstrom Macroglobulinaemia; Waldenstrom Macroglobulinemia; Waldenstrom's Macroglobulinaemia Refractory —
Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.
Full readout calendar →
Pipeline assets Iopofosine I 131
Phase 2 · Active Modality: radiopharmaceutical (phospholipid radioconjugate)
Aliases iopofosine, CLR 131
Target phospholipid (phospholipid radioconjugate)
Indications Relapsed/refractory Waldenstrom macroglobulinemia (WM) (Phase 2) Relapsed/refractory multiple myeloma (MM) (Phase 2) Relapsed/refractory CNS lymphoma (CNSL) (Phase 2) Pediatric high-grade glioma (HGG) (Phase 1) Recurrent head & neck cancer (+ external beam radiation) (Phase 1) Catalysts — 2026 (initiation underway) Status note Beta-emitting iodine-131 PRC. CLOVER WaM Phase 2 (pivotal registration, r/r WM ≥2 prior lines incl. BTKi failure): primary endpoint met, MRR 61.8%, ORR 83.6%, mDOR 17.8 months; 12-month follow-up reported May 5, 2026. Breakthrough Therapy Designation (r/r WM, Jun 4, 2025); EMA SAWP advised a Conditional Marketing Authorization filing for post-BTKi refractory WM could be acceptable (Oct 6, 2025). Phase 3 confirmatory study activities initiated Jun 2026. CLOVER-1 Phase 2b (r/r MM, r/r CNSL) closed to enrollment, patients in follow-up. Fatalities have occurred in patients post-treatment with iopofosine. $35M upfront + up to $105M milestone-based financing (May 5, 2026) funds Phase 3 initiation.
CLR 121125
Phase 1 · Active Modality: radiopharmaceutical (phospholipid radioconjugate)
Aliases CLR 125
Target phospholipid (phospholipid radioconjugate)
Indications Triple-negative breast cancer (TNBC) (Phase 1) Status note Iodine-125 Auger-emitting program; Phase 1b dose-finding study in TNBC.
CLR 121225
Stage not disclosed · Active Modality: radiopharmaceutical (phospholipid radioconjugate)
Aliases CLR 225
Target phospholipid (phospholipid radioconjugate)
Status note Actinium-225 based PRC listed as a lead program; no trial detail in the excerpts.
Per-asset detail extracted from the 10-Q filed 2026-08-13. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
Pipeline Lead drug Iopofosine I 131 Lead indication Waldenstrom Macroglobulinaemia Lead phase Phase 3 Active trials 5
Active clinical trials Trial Phase Status Role Sponsor BP Condition(s) Mgmt guide NCT07766421 Phase 3 Not yet recruiting Sponsor CLRB — Waldenstrom Macroglobulinaemia; Waldenstrom Macroglobulinemia; Waldenstrom's Macroglobulinaemia Refractory — NCT02952508 Phase 2 Active, not recruiting Sponsor CLRB — Waldenstrom Macroglobulinemia; Multiple Myeloma; Chronic Lymphocytic Leukemia — NCT07311993 Phase 1 Recruiting Sponsor CLRB — Breast Cancer — NCT05610891 Phase 1 Active, not recruiting Sponsor CLRB — High-Grade Glioma — NCT03478462 Phase 1 Active, not recruiting Sponsor CLRB — Pediatric Solid Tumor; Pediatric Lymphoma; Pediatric Brain Tumor —
Sponsor-matched active trials from ClinicalTrials.gov (5 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.
View all 5 active trials for Cellectar Biosciences, Inc. on ClinicalTrials.gov
No specialist-fund holders in 13F data for this company.
Fully Diluted · Free biotech stocks database. Figures are sourced from SEC filings and company disclosures; not investment advice.